PROCEPT BioRobotics (PRCT) stock surged 5.07% in intraday trading on Wednesday, following the company's impressive Q4 2024 earnings report that highlighted strong revenue growth and the successful launch of its new AI-enabled Hydro robotic system.
The company reported a 57% year-over-year increase in total revenue for Q4 2024, reaching $68.2 million, driven by increased sales of its Aquabeam and Hydro robotic systems, as well as a surge in procedures performed. Full-year 2024 revenue grew by an impressive 65% compared to the previous year.
A key driver of PROCEPT's growth was the introduction of the Hydro robotic system, featuring advanced AI and ultrasound integration, which has been well-received in the market. The company achieved a 60% growth in its US installed base, with 505 systems by the end of 2024, and the Hydro system accounted for 95% of new system sales in Q4.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。